查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888750

尿失禁藥物市場規模、佔有率和趨勢分析報告：按類型、藥物類別、性別、分銷管道、地區和細分市場預測（2025-2033 年）

Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress Incontinence, Urge Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

尿失禁藥物市場摘要

2024年全球尿失禁藥物市場規模估計為43.2億美元，預計2033年將達到69.5億美元。

預計從 2025 年到 2033 年，該行業將以 5.4% 的複合年成長率成長。這一成長主要受老年人口中尿失禁盛行率上升以及對有效治療性介入的需求不斷成長的推動。

根據 Dovepress 2023 年 5 月發布的報告，女性尿失禁的盛行率為 24.8%，其中 12.7% 為應力性尿失禁，8.0% 為混合性尿失禁，4.1% 為急性尿失禁。研究表明，患病率隨年齡和體重指數 (BMI) 的增加而逐漸升高，凸顯了早期診斷和有效治療的必要性。患者和醫護人員對尿失禁的意識提升，改善了診斷和治療率，從而促進了治療的普及。 BETA3 腎上腺素受體促效劑和抗膽鹼能藥物的進步改善了不同患者群體的治療效果，而口服藥物和非侵入性治療方法的普及提高了患者的用藥依從性。不斷擴展的零售和線上藥局網路確保了穩定的藥品供應，並增強了各地區的市場表現。

隨著製藥公司致力於開發標靶性強、安全性高的治療方法以滿足持續存在的未滿足醫療需求，市場正在不斷擴大。例如，2024年4月，Lupin公司在美國推出了用於治療膀胱過動症的學名藥藥Mirabegron（Mirbetriq的學名藥）。此類學名藥的出現以及新型作用機制的創新，豐富了治療選擇，提高了藥物的可及性。對旨在提高療效和減少副作用的研究項目的投入，為開發差異化治療方法創造了機會。品牌藥和學名藥並存，確保了成本的柔軟性，並有助於提高患者的治療依從性。主要企業與研究機構之間的策略合作，正在加速藥物研發進程，並拓展治療產品線。持續的生命週期管理和核准後監測，強化了產品定位，維持了長期競爭力和收入穩定性。

已開發地區和新興地區醫療保健支出的成長，以及泌尿系統和婦科醫療服務可近性的提高，進一步推動了市場擴張。例如，根據截至2025年10月的全球數據，預計60歲及以上人口將從2020年的10億增加到2050年的21億，翻倍。隨著人口的成長，尿失禁及相關老年疾病的負擔預計將會增加，從而推動對有效且易於獲得的治療方法的需求。醫療保健提供者正透過改善疾病管理來優先考慮老年人的生活品質，這推動了治療策略的創新。藥物傳遞技術的進步提高了治療的精準性和便捷性，而針對膀胱過動症和混合性尿失禁的臨床研究的不斷深入，則推動了聯合治療的開發。持續的創新、高效的分銷系統以及不斷成長的臨床應用預計將支持尿失禁治療市場在整個預測期內保持穩定的成長勢頭。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 尿失禁藥物市場變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 尿失禁藥物市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2024 年和 2033 年）
  • 市場規模、預測與趨勢分析（按類型分類，2021年至2033年）
  • 應力性尿失禁
  • 急性尿失禁
  • 溢出性尿失禁
  • 功能性尿失禁
  • 其他類型

5. 尿失禁藥物市場：依藥物類別分類的業務分析

  • 按藥物類別分類的市場佔有率（2024 年和 2033 年）
  • 市場規模、預測和趨勢分析（按藥物類別分類，2021-2033 年）
  • 抗膽鹼能藥物
  • BETA3-腎上腺素受體促效劑
  • α受體阻斷劑
  • 雌激素
  • 去氨加壓素
  • 三環抗憂鬱藥物
  • 其他藥物類別

6. 尿失禁藥物市場：性別業務分析

  • 按性別分類的市場佔有率（2024 年和 2033 年）
  • 市場規模、預測與趨勢分析（按性別分類，2021-2033 年）
  • 男性
  • 女士

7. 尿失禁藥物市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 市場規模、預測與趨勢分析（按分銷管道分類，2021-2033 年）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 尿失禁藥物市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2024 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析（按地區分類，2021-2033 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Pfizer Inc.
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bayer AG
    • Ferring Pharmaceuticals
Product Code: GVR-4-68040-366-2

Urinary Incontinence Therapeutics Market Summary

The global urinary incontinence therapeutics market size was estimated at USD 4.32 billion in 2024 and is projected to reach USD 6.95 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of urinary incontinence among aging populations and the growing demand for effective therapeutic interventions that address bladder dysfunction.

According to a May 2023 report by Dovepress, the prevalence of female urinary incontinence was found to be 24.8%, with stress incontinence accounting for 12.7%, mixed incontinence for 8.0%, and urgency incontinence for 4.1%. The study indicated that prevalence increased progressively with age and body mass index, emphasizing the need for early diagnosis and effective therapy. Rising awareness among patients and healthcare providers has improved diagnosis and management rates, supporting higher treatment adoption. Advancements in B3-adrenoceptor agonists and antimuscarinic agents are improving outcomes across patient groups, while wider access to oral and non-invasive options is enhancing adherence. Expanding retail and online pharmacy networks are ensuring consistent medication availability, reinforcing market performance across regions.

The market is expanding as pharmaceutical companies focus on developing targeted and safer therapies addressing persistent unmet needs. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Myrbetriq, aimed at managing overactive bladder in the U.S. The introduction of such generics and novel mechanisms of action is diversifying treatment options and improving accessibility. Investments in research programs to enhance efficacy and minimize side effects are creating opportunities for the development of differentiated therapies. The presence of branded and generic drugs ensures cost flexibility, improving treatment compliance. Strategic collaborations between leading players and research organizations are accelerating development timelines and expanding the therapeutic pipeline. Continuous lifecycle management and post-approval studies are reinforcing product positioning, sustaining long-term competitiveness, and revenue stability.

Market expansion is further supported by rising healthcare expenditures and increasing access to urology and women's health services across both developed and emerging regions. For instance, in October 2025, global data showed that the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As this population segment grows, the burden of urinary incontinence and related geriatric conditions is expected to rise, driving demand for effective and accessible treatment options. Healthcare providers are prioritizing the quality of life of older adults through improved disease management, which is stimulating innovation in therapeutic strategies. Advancements in drug delivery technologies are improving treatment precision and convenience, while expanded clinical research in overactive bladder and mixed incontinence is driving the evolution of combination regimens. Sustained innovation, efficient distribution systems, and growing clinical adoption are expected to maintain a stable growth trajectory for the urinary incontinence therapeutics market through the forecast period.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, drug class, gender, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Other Types
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Other Drug Classes
  • Gender Outlook (Revenue, USD Million, 2021 - 2033)
  • Male
  • Female
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Gender
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Stress Incontinence
    • 4.4.1. Stress Incontinence Market, 2021 - 2033 (USD Million)
  • 4.5. Urge Incontinence
    • 4.5.1. Urge Incontinence Market, 2021 - 2033 (USD Million)
  • 4.6. Overflow Incontinence
    • 4.6.1. Overflow Incontinence Market, 2021 - 2033 (USD Million)
  • 4.7. Functional Incontinence
    • 4.7.1. Functional Incontinence Market, 2021 - 2033 (USD Million)
  • 4.8. Other Types
    • 4.8.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2033
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 5.4. Anticholinergics
    • 5.4.1. Anticholinergics Market, 2021 - 2033 (USD Million)
  • 5.5. Beta-3 Adrenoceptor Agonists
    • 5.5.1. Beta-3 Adrenoceptor Agonists Market, 2021 - 2033 (USD Million)
  • 5.6. Alpha Blockers
    • 5.6.1. Alpha Blockers Market, 2021 - 2033 (USD Million)
  • 5.7. Estrogen
    • 5.7.1. Estrogen Market, 2021 - 2033 (USD Million)
  • 5.8. Desmopressin
    • 5.8.1. Desmopressin Market, 2021 - 2033 (USD Million)
  • 5.9. Tricyclic Antidepressants
    • 5.9.1. Tricyclic Antidepressants Market, 2021 - 2033 (USD Million)
  • 5.10. Other Drug Classes
    • 5.10.1. Other Drug Classes Market, 2021 - 2033 (USD Million)

Chapter 6. Urinary Incontinence Therapeutics Market: Gender Business Analysis

  • 6.1. Gender Market Share, 2024 & 2033
  • 6.2. Gender Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by gender, 2021 to 2033 (USD Million)
  • 6.4. Male
    • 6.4.1. Male Market, 2021 - 2033 (USD Million)
  • 6.5. Female
    • 6.5.1. Female Market, 2021 - 2033 (USD Million)

Chapter 7. Urinary Incontinence Therapeutics Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Urinary Incontinence Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Gender Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Gender Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Gender Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Gender Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Gender Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Gender Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Gender Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Gender Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Gender Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Gender Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Gender Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Gender Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Gender Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Gender Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Gender Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Gender Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Gender Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Gender Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Gender Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Gender Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Gender Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Gender Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Gender Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AbbVie Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Astellas Pharma Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Johnson & Johnson
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Viatris Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Teva Pharmaceutical Industries Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Sanofi S.A.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. GlaxoSmithKline plc
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Bayer AG
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Ferring Pharmaceuticals
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global urinary incontinence therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 6 Global urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 7 Global urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 10 North America urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 11 North America urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 12 North America urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 U.S urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 14 U.S urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 15 U.S urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 16 U.S urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Canada urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 19 Canada urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 20 Canada urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 22 Mexico urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 23 Mexico urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 24 Mexico urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 27 Europe urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 28 Europe urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 29 Europe urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 31 UK urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 UK urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 33 UK urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 35 Germany urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 36 Germany urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 37 Germany urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 39 France urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 40 France urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 41 France urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 43 Italy urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 44 Italy urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 45 Italy urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 47 Spain urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 48 Spain urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 49 Spain urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 51 Norway urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 52 Norway urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 53 Norway urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 55 Denmark urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 56 Denmark urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 57 Denmark urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 59 Sweden urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 60 Sweden urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 61 Sweden urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific urinary incontinence therapeutics market, by drug class, 2021-2033, (USD
  • Table 65 Asia Pacific urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 68 Japan urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 69 Japan urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 70 Japan urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 72 China urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 73 China urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 74 China urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 76 India urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 77 India urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 78 India urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 80 Australia urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 81 Australia urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 82 Australia urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 84 South Korea urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 85 South Korea urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 86 South Korea urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 88 Thailand urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 Thailand urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 90 Thailand urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 93 Latin America urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 94 Latin America urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 95 Latin America urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 96 Brazil urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 97 Brazil urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 98 Brazil urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 99 Brazil urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 100 Argentina urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 101 Argentina urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 102 Argentina urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 103 Argentina urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 109 South Africa urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 110 South Africa urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 111 South Africa urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 112 South Africa urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 117 UAE urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 118 UAE urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 119 UAE urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 120 UAE urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 121 Kuwait urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 123 Kuwait urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 124 Kuwait urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Urinary incontinence therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Urinary incontinence therapeutics market dynamics
  • Fig. 11 Urinary incontinence therapeutics market: Porter's five forces analysis
  • Fig. 12 Urinary incontinence therapeutics market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Stress Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 15 Urge Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 16 Overflow Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 17 Functional Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 18 Other Types market, 2021 - 2033 (USD Million)
  • Fig. 19 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 20 Anticholinergics market, 2021 - 2033 (USD Million)
  • Fig. 21 Beta-3 Adrenoceptor Agonists market, 2021 - 2033 (USD Million)
  • Fig. 22 Alpha Blockers market, 2021 - 2033 (USD Million)
  • Fig. 23 Estrogen market, 2021 - 2033 (USD Million)
  • Fig. 24 Desmopressin market, 2021 - 2033 (USD Million)
  • Fig. 25 Tricyclic Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 26 Other Drug Classes market, 2021 - 2033 (USD Million)
  • Fig. 27 Gender market, 2021 - 2033 (USD Million)
  • Fig. 28 Male market, 2021 - 2033 (USD Million)
  • Fig. 29 Female market, 2021 - 2033 (USD Million)
  • Fig. 30 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 31 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 32 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 33 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 34 Urinary incontinence therapeutics market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Latin America urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Middle East & Africa urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework